AtriCure, Inc. develops surgical and minimally invasive technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Company updates commonly cover quarterly and annual financial results, U.S. and international revenue trends, product adoption for AtriClip, cryoSPHERE, EnCompass and related device families, and clinical programs tied to Afib treatment and pain-blocking cryoablation.
Its disclosed product portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, AtriClip Left Atrial Appendage Exclusion System products, Hybrid AF Therapy, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation.
AtriCure, Inc. (Nasdaq: ATRC) reported first quarter 2021 revenue of $59.3 million, an increase of 11.4% year-over-year. U.S. revenue grew 15.7% to $50.3 million, driven by increasing sales in key product categories, while international revenue declined 8.1% to $9 million due to COVID-19 restrictions. The gross profit rose to $44.5 million with a gross margin of 75.1%. The company reported a net loss of $15.9 million, or $0.38 per share, an improvement from $0.42 per share a year earlier. AtriCure projects full year 2021 revenue between $252 million and $256 million.
AtriCure, Inc. (Nasdaq: ATRC) has appointed B. Kristine Johnson as Board Chair. Scott Drake and Mark Lanning will not seek re-election in May 2021. Johnson, who has been on the board since 2017, is President of Affinity Capital Management and has extensive experience in the healthcare sector, including a 17-year career at Medtronic. Drake, who has served on AtriCure's Board since 2013, and Lanning, a board member since 2006, have both contributed significantly to the company's growth.
AtriCure, a leader in Afib treatments, will release its Q1 2021 financial results on April 27, 2021. The company will also host a conference call at 4:30 PM ET to discuss these results, accessible by calling (844) 884-9951 (domestic) or (661) 378-9661 (international), using conference ID 3349395. AtriCure is recognized for innovative solutions, including the FDA-approved Isolator Synergy Ablation System for persistent Afib and the widely used AtriClip Left Atrial Appendage Exclusion System.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the Oppenheimer 31st Annual Healthcare Conference. The presentation is scheduled for March 16, 2021, at 1:10 p.m. Eastern Time. AtriCure offers innovative solutions, including the Isolator® Synergy™ Ablation System, the first FDA-approved device for treating persistent Afib, and the AtriClip® Left Atrial Appendage Exclusion System, the most widely sold LAA management device globally. For more details, visit AtriCure's investor page.
AtriCure, Inc. (Nasdaq: ATRC) reported its fourth quarter and full year 2020 financial results, revealing a 5.9% decline in Q4 revenue to $57.7 million, with a full year revenue decrease of 10.5% to $206.5 million, attributed to COVID-19 impacts on surgical procedures. Gross profit in Q4 was $42.4 million with a margin of 73.5%. Adjusted EBITDA improved to a positive $1.7 million in Q4. For 2021, revenue guidance is projected at $250 million, with anticipated adjusted EBITDA losses of $10 million. The first quarter forecast revenue ranges from $55 million to $57 million.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), has announced its participation in the SVB Leerink 10th Annual Global Healthcare Conference on February 24, 2021, at 8:00 a.m. ET. The event will feature a live and archived audio webcast available on the company's website. AtriCure’s innovative technologies, including the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, are widely utilized for Afib treatment, impacting over 33 million individuals globally. For further details, visit AtriCure.com.
AtriCure, Inc. (Nasdaq: ATRC) will release its fourth quarter and full year 2020 financial results on February 23, 2021.
The company will host a conference call at 4:30 p.m. ET on the same day to discuss these results. Interested parties can join the call via phone or listen to a live audio webcast on AtriCure's corporate website. AtriCure specializes in innovative technologies for treating atrial fibrillation (Afib) and left atrial appendage (LAA) management, offering FDA-approved devices that lead the market.
AtriCure, Inc. (ATRC) announced its preliminary financial results for Q4 and full-year 2020, reporting revenue of approximately $57.7 million in Q4, a 6% decline year-over-year, and about $206.5 million for the full year, down 11%. The company acknowledged the impact of COVID-19 on procedure volumes but noted a sequential revenue increase of 5% from Q3 2020. AtriCure emphasized its strong financial position and strategic progress, highlighting upcoming catalysts for growth in 2021, including new procedures and clinical trial data.
AtriCure, Inc. (Nasdaq: ATRC) has announced FDA 510(k) clearance for expanded labeling claims of its cryo nerve block therapy, now including treatment for adolescent patients aged 12-21. The cryoICE® and cryoSPHERE™ probes provide effective pain management post-surgery, particularly for procedures like the Nuss procedure for pectus excavatum. Collaborating with the UCSF-Stanford Pediatric Device Consortium, AtriCure aims to innovate pediatric medical devices efficiently. This expansion could enhance recovery experiences for younger patients undergoing invasive chest wall surgeries.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in the 39th Annual J.P. Morgan Healthcare Conference, scheduled for January 11, 2021, at 10:00 a.m. ET. A live audio webcast of the presentation will be available on the company's website. Additionally, AtriCure will attend one-on-one investor meetings at the Needham Annual Growth Conference on January 14, 2021. The company is known for its innovative technologies, including the FDA-approved Isolator® Synergy™ Ablation System and AtriClip® devices, which are widely used in Afib treatment.